Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial

Official title:

A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02466425
• Other study ID #: SHP465-305
• Status: Completed
• Phase: Phase 3
• Start date: June 18, 2015
• Est. completion date: February 16, 2016

Study information

• Verified date: May 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD in children and adolescents (aged 6-17 years). The primary objective of this study is to evaluate the efficacy of SHP465 administered as a daily morning dose compared to placebo in the treatment of children and adolescents (6-17 years of age inclusive) diagnosed with ADHD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 264
• Est. completion date: February 16, 2016
• Est. primary completion date: February 16, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Subject must be 6-17 years of age, inclusive, at the time of consent.

2. Subject's parent or legally authorized representative (LAR) must provide signature of informed consent, and there must be documentation of assent (if applicable) by the subject indicating that the subject is aware of the investigational nature of the study and the required procedures and restrictions in accordance with the ICH GCP Guideline E6 (1996) and applicable regulations before completing any study-related procedures.

3. Subject and parent/LAR are willing and able to comply with all of the testing and requirements defined in the protocol, including oversight of morning dosing. Specifically, the parent/LAR must be available at approximately 7:00AM (±2 hours) to dispense the dose of investigational product for the study duration.

4. Subject, who is a female and of child-bearing potential, must not have a positive serum beta human chorionic gonadotropin pregnancy test at the Screening Visit (Visit 1) and must have a negative urine pregnancy test at the Baseline Visit (Visit 2) and agree to comply with any applicable contraceptive requirements of the protocol.

5. Subject must have a satisfactory medical assessment with no clinically significant or relevant abnormalities.

6. Subject meets DSM-IV-TR criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation.

7. Subject has an ADHD-RS-IV Total Score >28 at the Baseline Visit (Visit 2).

8. Subject is functioning at an age-appropriate level intellectually, as determined by the study Investigator.

9. Subject is currently not on ADHD therapy, or is not completely satisfied with any aspect of their current ADHD therapy.

10. Subject is able to swallow a capsule whole.

Exclusion Criteria:

1. Subject has a current, controlled (with medications prohibited in this study) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any significant comorbid Axis II disorder or significant Axis I disorder (such as post-traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, depressive or anxiety disorder) or other symptomatic manifestations that, in the opinion of the examining clinician, will contraindicate treatment with SHP465 or confound efficacy or safety assessments. Comorbid psychiatric diagnoses will be established with the Screening Visit (Visit 1) interview of the K-SADS-PL and additional modules if warranted by the results of the initial interview. Subjects may continue participation in a behavioral modification program during the study as long as they have been participating in the program for at least 1 month at the time of the Baseline Visit (Visit 2).

2. Subject meets DSM-IV-TR diagnosis of conduct disorder. Oppositional defiant disorder is not exclusionary.

3. Subject is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator.

4. Subject is underweight based on Centers for Disease Control and Prevention body mass index (BMI)-for-age sex-specific values at the Screening Visit (Visit 1). Underweight is defined as a BMI <3rd percentile

5. Subject is significantly overweight based on Centers for Disease Control and Prevention BMI-for-age sex specific values at the Screening Visit (Visit 1). Significantly overweight is defined as a BMI >97th percentile for this study

6. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments conducted in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional condition(s) that, in the Investigator's opinion, would prohibit the subject from completing the study or would not be in the best interest of the subject. The additional conditions would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol. Mild, stable asthma is not exclusionary.

7. Subject has a history of seizure (other than infantile febrile seizures), a chronic or current tic disorder, or a current diagnosis of Tourette's Disorder. Subject has a history of tics that are judged by the Investigator to be exclusionary.

8. Subject's blood pressure measurements exceed the 90th percentile for age, sex, and height (based on the Blood Pressure Levels by Age and Height Percentile [for boys and girls]) at the Screening Visit (Visit 1) and the Baseline Visit (Visit 2)

9. Subject has a known history of hypertension

10. Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place him/her at increased vulnerability to the sympathomimetic effects of a stimulant medication.

11. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.

12. Subject has any clinically significant ECG or clinically significant laboratory abnormality at the Screening Visit (Visit 1).

13. Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone and thyroxine at the Screening Visit (Visit 1). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.

14. Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.

15. Subject has failed to respond, based on Investigator judgment, to an adequate course(s) (dose and duration) of amphetamine therapy

16. Subject has a history of suspected substance abuse or dependence disorder (excluding nicotine) in accordance with DSM-IV-TR criteria. Subjects with a lifetime history of amphetamine, cocaine, or other stimulant abuse and/or dependence will be excluded.

17. Subject has a positive urine drug result at the Screening Visit (Visit 1) (with the exception of subject's current stimulant therapy, if any) or the Baseline Visit (Visit 2), if repeated unless the Investigator can verify that the positive result at the Screening Visit (Visit 1) is attributed to medication that has been prescribed to the subject and will be discontinued prior to the Baseline Visit (Visit 2). A positive result at the Screening Visit (Visit 1) attributed to a prescribed medication requires a re-test and a negative result at the Baseline Visit (Visit 2) to confirm subject eligibility.

18. Subject has taken another investigational product or has taken part in a clinical study within 30 days prior to the Screening Visit (Visit 1).

19. Subject has previously completed, discontinued, or was withdrawn from this study.

20. Subject is taking any medication that is excluded or has not been appropriately washed out according to the protocol requirements.

21. Subject is required to take or anticipates the need to take medications that have central nervous system effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.

22. Subject is female and is pregnant or lactating

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention Deficit Hyperactivity Disorder (ADHD)
• Hyperkinesis

Intervention

Drug:
• SHP465
12.5mg and 25mg capsules (one capsule daily)
• Placebo
Matching placebo capsule that appear identical in size, weight, shape, color

Locations

Country	Name	City	State
United States	Rainbow Research	Barnwell	South Carolina
United States	Florida Clinical Research Center, Llc	Bradenton	Florida
United States	McB Clinical Research Centers	Colorado Springs	Colorado
United States	Futuresearch Trials of Dallas, Lp	Dallas	Texas
United States	Midwest Clinical Research Center	Dayton	Ohio
United States	Harmonex Neuroscience Research	Dothan	Alabama
United States	Sarkis Clinical Trials	Gainesville	Florida
United States	Bayou City Research	Houston	Texas
United States	Houston Clinical Trials, Llc	Houston	Texas
United States	Red Oak Psychiatry Associates, Pa	Houston	Texas
United States	Clinical Neuroscience Solutions, Inc.	Jacksonville	Florida
United States	Eastside Therapeutic Resource	Kirkland	Washington
United States	Center For Psychiatry and Behavioral Medicine	Las Vegas	Nevada
United States	Capstone Clinical Research	Libertyville	Illinois
United States	Westex Clinical Investigations	Lubbock	Texas
United States	Northwest Behavioral Research Center	Marietta	Georgia
United States	Clinical Neuroscience Solution, Inc	Memphis	Tennessee
United States	Coastal Carolina Research Center	Mount Pleasant	South Carolina
United States	Baber Research Group Inc	Naperville	Illinois
United States	Louisiana Research Associates, Inc	New Orleans	Louisiana
United States	Psychiatric Care and Research Center	O'Fallon	Missouri
United States	Nrc Research Institute	Orange	California
United States	Medical Research Group of Central Florida	Orange City	Florida
United States	Clinical Neuroscience Solutions, Inc.	Orlando	Florida
United States	Psychiatric Associates	Overland Park	Kansas
United States	Research Across America	Plano	Texas
United States	Rochester Center For Behavioral Medicine	Rochester Hills	Michigan
United States	Midwest Research Group	Saint Charles	Missouri
United States	Oregon Center For Clinical Investigations, Inc	Salem	Oregon
United States	Pcsd Feighner Research	San Diego	California
United States	Miami Research Associates, Llc	South Miami	Florida
United States	Encompass Clinical Research	Spring Valley	California
United States	Tulsa Clinical Research, Llc	Tulsa	Oklahoma
United States	Omega Medical Research	Warwick	Rhode Island
United States	Janus Center For Psychiatric Research	West Palm Beach	Florida
United States	Elite Clinical Trials, Inc	Wildomar	California

Sponsors (1)

Lead Sponsor	Collaborator
Shire

Country where clinical trial is conducted

United States, 

References & Publications (1)

Brams M, Childress AC, Greenbaum M, Yu M, Yan B, Jaffee M, Robertson B. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Attention-Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score at Visit 6 (Week 4)	The ADHD-RS-IV consists of 18 items designed to reflect current symptomatology of ADHD based on diagnostic and statistical manual of mental disorders, fourth edition - text revision (DSM-IV-TR) criteria. Each item is scored on a 4-point scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items may be grouped into 2 subscales: hyperactivity/impulsivity (even-numbered items 2-18) and inattentiveness (odd-numbered items 1-17). Higher score = more severe symptoms.	Baseline, Visit 6 (Week 4)
Secondary	Clinical Global Impression of Improvement (CGI-I) at Visit 6 (Week 4)	CGI-I was performed to rate the severity of a participant's condition on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).	Visit 6 (Week 4)